Every 8-K that Impact BioMedical, Inc. (IBO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IBO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IBO filings page.
Impact BioMedical Inc. (IBO) completed a 1-for-12.62 reverse stock split, effective September 23, 2026. The company said issued and outstanding common shares decreased from approximately 107.8 million to approximately 8.6 million.
The split did not change authorized share counts, par value or common-stock voting rights. No fractional shares were issued; holders otherwise entitled to a fractional share received one full post-split share.
IMPACT BIOMEDICAL INC. (symbol: IBO) is the issuer of record for a Form 8-K filing submitted to the SEC.
Impact Biomedical Inc. (IBO) approved a 1-for-12.62 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on September 23, 2026. The split is intended to support a proposed merger with Zoar Limited and efforts to regain compliance with NYSE American continued listing requirements, though it does not assure either outcome.
Every 12.62 issued and outstanding shares will be combined into one share, reducing the outstanding common shares from approximately 107,821,231 to approximately 8,543,679, with fractional shares rounded up to the nearest whole share. Proportional adjustments will be made to equity awards, related exercise prices, and shares reserved under equity plans, while authorized share capital remains unchanged, so ownership percentages are expected to stay the same apart from rounding. The company also corrected its previously announced merger exchange ratio, confirming Impact stockholders are expected to receive one Zoar Limited share for every one Impact share held immediately prior to the merger’s effective time, after giving effect to the reverse split.
Impact BioMedical Inc. amended its merger, voting, and transition agreements tied to its planned business combination with Dr Ashleys. PubCo will issue 22,000 compensation shares to Impact’s CEO and up to 128,000 ordinary shares to DSS, Inc., all deducted from the Company Share Consideration.
The amended definition provides for 169,560,000 PubCo ordinary shares as Company Share Consideration, representing 94.20% of PubCo’s outstanding shares at Closing, before compensation and DSS shares. The merger End Date was extended from March 31, 2026 to July 1, 2026, and supporting stockholders now collectively hold 92,980,843 Impact shares, or about 88.87% on a fully diluted basis.
DSS, Inc. agreed to funding and hold harmless obligations and to support Impact’s co-signing of certain loan agreements, in return for the DSS share grants, which are intended to be fully paid, non-assessable, registered, and freely tradable under the Securities Act, subject to an effective registration statement.
Impact Biomedical Inc. (IBO) reported results of its 2025 annual meeting of stockholders. A quorum of 64,328,010 shares, representing 88.50% of shares outstanding and eligible to vote as of September 8, 2025, was present in person or by proxy.
Stockholders elected eight directors—Frank D. Heuszel, Elise Brownell, Melissa Sims, Castel(l) Hibbert, David Keene, Christian Zimmerman, Jason Grady, and Chan Heng Fai Ambrose—to serve until the next annual meeting. They also ratified Grassi & Co. Certified Public Accountants, P.C. as independent auditor for fiscal year 2025 with votes 64,126,924 for, 174,317 against, and 26,769 abstain. On an advisory basis, stockholders approved executive compensation with 61,512,770 for, 107,684 against, 4,795 abstain, and 2,702,761 broker non‑votes.
Impact BioMedical Inc. announced the conversion of its Series A Convertible Preferred Stock into common stock under Section 6 of the Certificate of Designation dated October 30, 2023. The holder, DSS BioHealth Security, Inc., elected the Optional Conversion permitted seventy-five days after issuance.
Following this election, DSS BioHealth Security, Inc. is deemed the record holder of 60,496,041 shares of the Company’s common stock, $0.001 par value per share. The event was reported as of October 24, 2025.
Impact BioMedical (NYSE:IBO) disclosed in an 8-K that it signed a Merger and Share Exchange Agreement on 21 June 2025 with Dr Ashleys Cayman, newly formed PubCo Dr Ashleys Limited and related entities.
Transaction structure: (i) Merger Sub will merge into Impact, making Impact a wholly-owned subsidiary of PubCo; (ii) immediately after, PubCo will acquire 100% of Dr Ashleys Cayman. Post-closing ownership will be 94.20 % Dr Ashleys Cayman shareholder, 4.80 % Impact shareholders and 1.00 % BMI Capital. A reverse stock split of Impact shares will occur immediately before closing to facilitate the exchange ratio.
Consideration mechanics: each Impact common share, preferred conversion share, option and warrant (after conversion/cancellation) will be exchanged for PubCo ordinary shares representing the 4.80 % aggregate stake. Impact must have ≥ $10,000 net cash and zero net debt at closing. NYSE American must conditionally approve listing of PubCo shares.
Governance changes: Impact will be renamed "Dr Ashleys USA Inc."; all current Impact directors and officers will resign. New board and officers for both Impact and PubCo will be designated by Dr Ashleys Cayman. Support agreements covering 86.81 % of Impact’s shares commit to vote in favour of the deal.
Key conditions & rights: customary accuracy of reps & warranties, absence of material adverse effect, effectiveness of a registration statement, no blocking injunctions, and termination rights for breach or superior proposals. A Transition Agreement with DSS, Inc. was executed to ensure orderly hand-over of operations.
The filing attaches the Merger Agreement (Exhibit 2.1), Voting Agreement (Exhibit 10.1) and Transition Agreement (Exhibit 10.2) for full terms.